Screening Patients With Central Nervous System Tumors for Participation in National Cancer Institute Clinical Trials - Tabular View

Tracking Information

First Received Date ^ICMJE

July 8, 2002

Last Updated Date

May 7, 2009

Start Date ^ICMJE

April 2002

Estimated Primary Completion Date

December 2010 (final data collection date for primary outcome measure)

Current Primary Outcome Measures ^ICMJE

Entry onto investigational study [ Designated as safety issue: No ]

Original Primary Outcome Measures ^ICMJE

Entry onto investigational study

Change History

Complete list of historical versions of study NCT00040924 on ClinicalTrials.gov Archive Site

Current Secondary Outcome Measures ^ICMJE

Original Secondary Outcome Measures ^ICMJE

Descriptive Information

Brief Title ^ICMJE

Screening Patients With Central Nervous System Tumors for Participation in National Cancer Institute Clinical Trials

Official Title ^ICMJE

Eligibility Screening Of Patients With Central Nervous System Tumors For The National Cancer Institute's (NCI) Clinical Research Protocols

Brief Summary

RATIONALE: Screening tests may help doctors determine which patients are eligible for treatment on clinical trials.

PURPOSE: This clinical trial is screening patients with central nervous system tumors for participation in National Cancer Institute (NCI) clinical trials.

Detailed Description

OBJECTIVES:

Evaluate patients with central nervous system tumors for eligibility in NCI primary clinical research protocols.

OUTLINE: Patients undergo various diagnostic procedures and clinical testing to determine eligibility for participation in NCI CNS tumor primary clinical research protocols. Patients undergo imaging scans; laboratory testing of blood, cerebrospinal fluid, bone marrow, urine, and other specimens as needed to determine protocol eligibility; and other specific organ function tests.

PROJECTED ACCRUAL: A maximum of 3,000 patients will be accrued for this study within 5 years.

Study Phase

Study Type ^ICMJE

Interventional

Study Design ^ICMJE

Screening

Condition ^ICMJE

Brain and Central Nervous System Tumors
Lymphoma

Intervention ^ICMJE

Other: cytology specimen collection procedure
Other: physiologic testing

Study Arms / Comparison Groups

Publications *

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status ^ICMJE

Recruiting

Estimated Enrollment ^ICMJE

3000

Completion Date

Estimated Primary Completion Date

December 2010 (final data collection date for primary outcome measure)

Eligibility Criteria ^ICMJE

DISEASE CHARACTERISTICS:

Diagnosis of CNS tumor or a history of a CNS tumor
Being evaluated for primary clinical research protocols within NCI

PATIENT CHARACTERISTICS:

Age:

Any age

Performance status:

Not specified

Life expectancy:

Not specified

Hematopoietic:

Not specified

Hepatic:

Not specified

Renal:

Not specified

Other:

No other concurrent serious medical condition that would preclude screening procedures

PRIOR CONCURRENT THERAPY:

Biologic therapy:

Not specified

Chemotherapy:

Not specified

Endocrine therapy:

Not specified

Radiotherapy:

Not specified

Surgery:

Not specified

Gender

Both

Ages

Accepts Healthy Volunteers

Contacts ^ICMJE

Location Countries ^ICMJE

United States

Administrative Information

NCT ID ^ICMJE

NCT00040924

Responsible Party

Study ID Numbers ^ICMJE

CDR0000069420, NCI-02-C-0186

Study Sponsor ^ICMJE

National Cancer Institute (NCI)

Collaborators ^ICMJE

Investigators ^ICMJE

Principal Investigator:

Howard A. Fine, MD

NCI - Neuro-Oncology Branch

Information Provided By

National Cancer Institute (NCI)

Verification Date

April 2008

^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP